公开(公告)号：US11986456B2

公开(公告)日：2024-05-21

申请号：US18076444

申请日：2022-12-07

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61K9/00 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

CPC classification number: A61K31/327 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/10 ,  A61K9/107 ,  A61K9/50 ,  A61P17/00 ,  A61P17/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

公开(公告)号：US11541026B2

公开(公告)日：2023-01-03

申请号：US17541847

申请日：2021-12-03

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Karine Neimann ,  Ofer Toledano

IPC: A61K31/327 ,  A61P17/10 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61P17/00 ,  A61K9/50 ,  A61K9/10

Abstract: A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

公开(公告)号：US11633399B2

公开(公告)日：2023-04-25

申请号：US16737503

申请日：2020-01-08

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Moshe Arkin ,  Marcel Zighelboim ,  Ori Nov ,  Ofer Toledano ,  Karine Neimann

IPC: A61K31/505 ,  A61K31/517 ,  A61K31/5377 ,  A61K39/395 ,  A61K9/00 ,  A61K45/06 ,  A61K31/05 ,  A61K9/06 ,  A61K31/506

Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.

公开(公告)号：US20210236432A1

公开(公告)日：2021-08-05

申请号：US17166336

申请日：2021-02-03

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Marcel Zighelboim ,  Karine Neimann ,  Hila Hakak Djerbi

IPC: A61K9/50 ,  A61K31/44 ,  A61K9/06

Abstract: Provided herein is a topical composition comprising roflumilast, roflumilast N-oxide or salts thereof as an active agent. The active agent in the composition of this invention is in encapsulated or non-encapsulated form, according to need.
The above composition is useful for the treatment, prevention or alleviation of a skin disorder selected from Hidradenitis suppurativa and Prurigo nodularis.

公开(公告)号：US20190015369A1

公开(公告)日：2019-01-17

申请号：US15978146

申请日：2018-05-13

Applicant: SOL-GEL TECHNOLOGIES LTD.

Inventor： Moshe Arkin ,  Stephen Cherkez ,  Ofer Toledano

IPC: A61K31/203 ,  A61K47/14 ,  A61K9/50 ,  A61K31/327 ,  A61K9/00

Abstract: The present disclosure relates to methods of treatment of acne in a patient in need thereof, comprising the concomitant once daily topical administration of from about 20 w/w to about 10% w/w of solid particulate benzoyl peroxide (BPO) and from about 0.01% w/w to about 0.1% w/w of solid particulate all trans retinoic acid (ATRA) for a period of up to 3 months, wherein the side-effects of the two actives are medically acceptable and wherein the therapeutic effect of BPO and ATRA is superior to the effect of each active administered alone. The concomitant administration may be carried out by once daily administration to a patient in need thereof of a single composition or of a first composition comprising BPO and a second composition comprising ATRA from a dual chamber dispenser or from two separate dispensers, mixed before applying on the skin of a patient in need thereof for up to 2 weeks, up to 1 month, preferably up to 2 months and more preferably up to 3 months.

公开(公告)号：US20230357113A1

公开(公告)日：2023-11-09

申请号：US18144297

申请日：2023-05-08

Applicant: Sol-Gel Technologies Ltd.

Inventor： Moshe Arkin ,  Natalie Utsis ,  Ariel Mitelman ,  Bar Havazelt ,  Shai Dan

IPC: C07C37/84

CPC classification number: C07C37/84 ,  C07B2200/13

Abstract: The present invention relates to crystalline polymorphs of Tapinarof, e.g., Tapinarof crystalline Form B, Form C, and Form D, pharmaceutical compositions comprising the same, processes for preparation thereof, and uses thereof for treatment of skin disorders.